Effect of anticoagulants and antiplatelet agents on the efficacy of intravesical BCG treatment of bladder cancer: A systematic review

Journal of the Canadian Urological Association

Volumn 7, Issue 11-12, 2013, Pages

  Fahmy, Nader ^a   Lazo Langner, Alejandro ^b   Iansavichene, Alla E ^c   Pautler, Stephen E ^a  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84887348395     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.1213     Document Type: Review

References (25)

1. Canadian Cancer Society's Steering Committee on Cancer Statistics: Canadian Cancer Statistics (2012). http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20 cancer%20statistics/Canadian-Cancer-Statistics-2012---English.pdf. Accessed October 29, 2013.
2. Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 2006;49:790-7. http://dx.doi.org/10.1016/j.eururo.2006.01.017
3. Zlotta AR, Fleshner NE, Jewett MA. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J 2009;3:S199-205.
4. Kavoussi LR, Brown EJ, Ritchey JK, et al. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 1990;85:62-7. http://dx.doi.org/10.1172/JCI114434
5. Ratliff TL, Palmer JO, McGarr JA, et al. Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. Cancer Res 1987;47:1762-6.
6. Hudson MA, Brown EJ, Ritchey JK, et al. Modulation of fibronectin-mediated Bacillus Calmette-Guerin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res 1991;51:3726-32.
7. Shen ZJ, Wang Y, Ding GQ, et al. Study on enhancement of fibronectin-mediated bacillus Calmette-Guerin attachment to urinary bladder wall in rabbits. World J Urol 2007;25:525-9. http://dx.doi.org/10.1007/ s00345-007-0198-z
8. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-12. http://dx.doi.org/10.1016/j. jclinepi.2009.06.005
9. Yuge K, Kikuchi E, Tanaka N, et al. Clinical impact of anti-platelet medication in patients with non-muscle invasive bladder cancer treated with BCG therapy. Urology 2012;80:S218.
10. Boorjian SA, Berglund RK, Maschino AC, et al. Fibrin clot inhibitor medication and efficacy of bacillus Calmette-Guerin for bladder urothelial cancer. J Urol 2009;182:1306-12. http://dx.doi.org/10.1016/j. juro.2009.06.026
11. Gee JR, Jarrard DF, Bruskewitz RC, et al. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guerin. BJU Int 2009;103:736-9. http://dx.doi.org/10.1111/ j.1464-410X.2008.08123.x
12. Heiner JG, Terris MK. Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guerin therapy. Urol Oncol 2008;26:137-40. http://dx.doi.org/10.1016/j. urolonc.2007.04.005
13. Hudson MA, Yuan JJ, Catalona WJ, et al. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors. J Urol 1990;144:1362-4.
14. Rogerson JW. Intravesical bacille Calmette-Guerin in the treatment of superficial transitional cell carcinoma of the bladder. Br J Urol 1994;73:655-8.
15. P'Ng K B, Walsh MD, Seymour GJ, et al. The adverse effect of fibrin-clot inhibiting drugs on intravesical bacillus Calmette-Guerin efficacy for superficial bladder cancer. Aust N Z J Surg 1993;63:127-30.
16. Witjes JA, Meijden AP, Doesburg W, et al. Influence of fibrin clot inhibitors on the efficacy of intravesical Bacillus Calmette-Guerin in the treatment of superficial bladder cancer. The Dutch Southeast Cooperative Urological Group. Eur Urol 1993;23:366-70.
17. Zuiverloon TC, Nieuweboer AJ, Vekony H, et al. Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 2012;61:128-45. http://dx.doi.org/10.1016/j.eururo.2011.09.026
18. Alexandroff AB, Jackson AM, O'Donnell MA, et al. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999;353:1689-94. http://dx.doi.org/10.1016/S0140-6736(98)07422-4
19. Hudson MA, Ritchey JK, Catalona WJ, et al. Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria. Cancer Res 1990;50:3843-7.
20. Pan CW, Shen ZJ, Ding GQ. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study. J Urol 2008;179:1307-11. http:// dx.doi.org/10.1016/j.juro.2007.11.045
21. Jaeger TF. Categorical Data Analysis: Away from ANOVAs (transformation or not) and towards Logit Mixed Models. J Mem Lang 2008;59:434-46. http://dx.doi.org/10.1016/j.jml.2007.11.007
22. See WA, Chapman PH. Heparin prevention of tumor cell adherence and implantation on injured urothelial surfaces. J Urol 1987;138:182-6.
23. See WA, Miller JS, Williams RD. Pathophysiology of transitional tumor cell adherence to sites of urothelial injury in rats: mechanisms mediating intravesical recurrence due to implantation. Cancer Res 1989;49:5414-8.
24. Mohammed SI, Knapp DW, Bostwick DG, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999;59:5647-50.
25. Dovedi SJ, Kirby JA, Atkins H, et al. Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer. J Urol 2005;174:332-7. http:// dx.doi.org/10.1097/01.ju.0000161589.85869.ae